Persistence of Immunologic Memory for Twelve Years in Children Given Hepatitis B Vaccine in Infancy

West, David J.; Watson, Barbara; Lichtman, Jeremy; Hesley, Teresa M.; Hedberg, Kathleen

doi:10.1097/00006454-199408000-00015

Cited by 38 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[7,17] Because of the progressive decline of anti-HBs and increased likelihood of development of new HBV infections, some investigators suggested the use of a booster vaccination. [8,18] However, a preponderance of data indicate that the protective efficacy of HBV vaccines can last for at least 5 years, and a booster before 5 years is not necessary.…”

Section: Discussionmentioning

confidence: 99%

Persistence of antibody to hepatitis B surface antigen among vaccinated children in a low hepatitis B virus endemic area

Aghakhani

Banifazl²,

Izadi

et al. 2011

World J Pediatr

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Persistence of antibody to hepatitis B surface antigen among vaccinated children in a low hepatitis B virus endemic area

Aghakhani

Banifazl²,

Izadi

et al. 2011

World J Pediatr

View full text Add to dashboard Cite

show abstract

“…Our previous study suggests that routine booster vaccination may not be necessary to provide protection against chronic HBV infection before age 15 years in Taiwan (11), as the maintenance of HBsAg-specific memory confers protection against a clinical breakthrough infection even in the absence of detectable antibodies (5,17,19). However, the possibility of a need for a booster dose exists, particularly when the child becomes a sexually active adolescent.…”

Section: Discussionmentioning

confidence: 99%

Long-Term Follow-Up of Hepatitis B Surface Antibody Levels in Subjects Receiving Universal Hepatitis B Vaccination in Infancy in an Area of Hyperendemicity: Correlation between Radioimmunoassay and Enzyme Immunoassay

Wang

Chang

et al. 2005

Clin Vaccine Immunol

View full text Add to dashboard Cite

The aims of the present study were to determine (i) the long-term immunogenicity and the decay rate of hepatitis B virus (HBV) surface antibody (anti-HBs) from universal hepatitis B vaccination at infancy for a healthy population in an area of hyperendemicity and (ii) whether the anti-HBs levels measured by enzyme immunoassay (EIA) were closely correlated with those assayed by radioimmunoassay (RIA) methods during long-term monitoring. A total of 1,337 apparently healthy children (696 boys and 641 girls) who were vaccinated against HBV at infancy and monitored for anti-HBs annually from 7 to 16 years of age entered the study. Serum samples were analyzed for anti-HBs by RIA at 7 to 15 years of age and were also analyzed by EIA at 13 to 16 years of age. Antibody titers were quantified in mIU/ml by EIA as well as by the ratio of the count in the sample to the count for a negative control (S/N) by RIA. In nonboosted children, the average decay of anti-HBs from 7 to 16 years of ages indicated that approximately 20% of the geometric mean titer decays per year. There was a good correlation between serum anti-HBs levels measured by the RIA and the EIA methods (r ‫؍‬ 0.91; P < 0.0001). An equation for RIA to EIA level conversion was established: log EIA titer ‫؍‬ ؊0.12 ؉ (1.31 · log RIA S/N). The anti-HBs titers measured by EIA correlate well with the S/N assayed by RIA. The annual decay rate of the log anti-HBs level may help in planning booster immunizations for hyporesponders or individuals at risk in adolescence.Hepatitis B virus (HBV) infection is a global health problem, particularly in areas of endemicity. In Taiwan, before the implementation of hepatitis B control, up to 15% to 20% of the general population were chronic carriers of hepatitis B surface antigen (HBsAg) and perinatal HBV transmission accounted for 40% to 50% of the carrier pool (1,15,16). Taiwan launched the world's first nationwide universal vaccination program in 1984, which resulted in a significant reduction in the chronic carrier rate in children from 10% to Ͻ1% over 15 years (13). The morbidity and mortality rates associated with the sequelae of chronic HBV infection also declined, as demonstrated by the reduction in the rates of childhood hepatocellular carcinoma (3). We previously reported on the adequate protection against HBV for up to 14 years following universal HBV vaccination in infancy in Taiwan (11). Yet, we also noted the waning immunity to the HBV vaccine and the possible need for a booster dose in the future. We therefore studied the decay rate of HBV surface antibody (anti-HBs) with time.During our long-term follow-up study, the methods for antiHBs determination shifted from radioimmunoassay (RIA) to enzyme immunoassay (EIA) due to the trend of reductions in the use of radioisotopes. We found that HBV serologic markers measured by different laboratory methods evolving from RIA during the first 6 years of follow-up to EIA during the last 2 years of follow-up made the interpretation of long-term antiHBs persistence difficult. Becau...

show abstract

“…Adults who develop a protective antibody response are protected from clinical disease and chronic infection. Long-term studies of immunized adults and children indicate that immune memory remains intact for at least 12 years, even though antiHBs levels may become low or undetectable (272,279,280). Routine booster doses of hepatitis B vaccine are not considered necessary (61).…”

Section: Vaccination Against Hbv Infection Prevention Of Hbv Infectiomentioning

confidence: 99%

Risk and Management of Blood-Borne Infections in Health Care Workers

Beltrami¹,

Williams

Shapiro

et al. 2000

Clinical Microbiology Reviews

355

209

View full text Add to dashboard Cite

Persistence of Immunologic Memory for Twelve Years in Children Given Hepatitis B Vaccine in Infancy

Cited by 38 publications

References 0 publications

Persistence of antibody to hepatitis B surface antigen among vaccinated children in a low hepatitis B virus endemic area

Persistence of antibody to hepatitis B surface antigen among vaccinated children in a low hepatitis B virus endemic area

Long-Term Follow-Up of Hepatitis B Surface Antibody Levels in Subjects Receiving Universal Hepatitis B Vaccination in Infancy in an Area of Hyperendemicity: Correlation between Radioimmunoassay and Enzyme Immunoassay

Risk and Management of Blood-Borne Infections in Health Care Workers

Contact Info

Product

Resources

About